Announced Thu, 23 Jul · 16:01 IST
Thyrocare Q1FY27: Revenue up 24%, PAT up 34% on strong volume growth
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+7.0%1-day move
₹544.95
prior close
₹560.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+5.4+3.1+1.3+4.2+7.0—————————
Up moveDown movePending
AI summary
Thyrocare reported Q1FY27 consolidated revenue of INR 240.02 Cr, up 24% YoY, driven by 26% growth in the Pathology segment. EBITDA rose 34% YoY to INR 77.27 Cr, and PAT surged 34% YoY to INR 51.33 Cr. The company processed 55.2 million tests, up 28% YoY, with franchise revenue up 27% and partnership revenue up 26%. Expanded into specialty diagnostics with allergy and genomics.
Likely market impact
Strong growth across revenue, EBITDA, and PAT signals robust momentum and margin expansion. Specialty diagnostics adds future growth optionality.